Cerba HealthCare S.A.S.

What Cerba HealthCare S.A.S. does

Cerba HealthCare S.A.S. is a France-headquartered private medical diagnostics group founded in 1967 and owned primarily by EQT AB alongside PSP Investments and BPIFrance. It operates more than 1,360 laboratories and 170 technical platforms across 5 continents, employing roughly 14,000-15,000 people worldwide and serving approximately 47 million patients per year. The group's portfolio covers routine clinical pathology through the Cerballiance network in France and abroad, specialized reference testing from its core Cerba laboratory, anatomo-cytopathology via Cerba Path, and clinical-trial central-lab services through Cerba Research (including Viroclinics-DDL for virology/immunology and CIRION BioPharma Research for bioanalytical work).

Cerba's product surface extends beyond conventional testing into preventive health checks under the Biopredix brand, sports performance testing under Cerba Sport, and novel biomarker diagnostics such as the pTau217 blood test launched in May 2026 as the first private European deployment at scale for earlier Alzheimer's diagnosis. It is layering digital infrastructure on top of its laboratory network through the OUTSCALE Healthcare Sovereign Platform developed with Dassault Systèmes for AI-powered patient care management on sovereign cloud, and is exploring needle-free sample collection with Loop Medical and drone logistics for biological samples. The group operates internationally through wholly-owned subsidiaries in Belgium (Cerba HealthCare Belgium, Ketterthill in Luxembourg), Italy (via the 2021 Lifebrain acquisition valued at nearly €1.2 billion), Canada (CIRION), and a network of joint ventures covering Africa (Cerba Lancet Africa) and the Middle East (Cerba HealthCare Saudi Arabia, formed 2023).

Revenue is generated primarily through routine testing reimbursed via national health systems and insurance, quote-based clinical trial services to pharmaceutical and biotech sponsors via Cerba Research, and specialized diagnostic testing including genetics, anatomo-cytopathology, and preventive check-ups. Marketing and distribution are dominated by direct laboratory and B2B enterprise channels, supported by corporate communications, industry events (Wired Health, Formathon), the Institut Cerba endowment fund, and a virtual incubator for health-tech startups. The group carries a €5 billion debt pile requiring a reduction plan as of 2026 and underwent a major leadership refresh through 2024-2025 with Julien Samson appointed Group CEO effective June 30, 2025.

Name

Cerba HealthCare S.A.S.

Legal name

Cerba HealthCare S.A.S.

Website

https://cerbahealthcare.com

Company type

Private

Founded year

1967

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Cerba HealthCare S.A.S. is a France-based private medical diagnostics group operating 1,360 laboratories and 170 technical platforms across 5 continents, serving 47 million patients annually with routine, specialized, and clinical-trial pathology services under brands such as Cerballiance, Cerba, Cerba Research, and Cerba Path.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

akta.pro secondary industry

Environmental Public Health Laboratories (Water/Air/Soil) (HLAJAIAG)

Keywords

• Clinical pathology services
• Medical diagnostic testing
• Specialty reference laboratory
• Clinical trials central lab
• Preventive health screening

Headquarters

HQ city

Saint-ouen-l'aumone

HQ country

France

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Medical Biology Testing Services: Cerba HealthCare generates revenue primarily through providing clinical pathology and medical biology testing services to patients, healthcare professionals, and institutions through its network of laboratories.
2. Clinical Trials Support Services: Through Cerba Research division, the company provides clinical pathology services for clinical trials serving biotechnology, pharmaceutical, and in vitro diagnostics industries globally.
3. Specialized Diagnostic Testing: Revenue from specialized testing including genetic testing, anatomo-cytopathology, and preventive medicine check-ups (Biopredix).

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Cerba HealthCare is an international medical diagnostics group operating routine clinical pathology (Cerballiance), specialized reference laboratory testing (Cerba), anatomo-cytopathology (Cerba Path), central laboratory services for clinical trials (Cerba Research), medical imaging and preventive screening (Biopredix), backed by approximately 1,360 laboratories across five continents serving 47 million patients each year.

Product overview

Cerba HealthCare is a leading medical diagnostics company offering a comprehensive portfolio of clinical pathology services across multiple brands and geographies. The core offering includes routine clinical pathology through the Cerballiance network in France and specialized testing through Cerba laboratories. The company operates across 1,360 laboratories worldwide serving 47 million patients annually. The product ecosystem includes: Cerballiance (routine labs), Cerba (specialized/reference labs), Cerba Research (clinical trials), Cerba Path (anatomopathology), Cerba Lancet Africa (African network), and international operations in Italy and Belgium/Luxembourg. Supporting services include preventive health checks (Biopredix), sports performance testing (Cerba Sport), and AI-powered patient care management (OUTSCALE Healthcare Sovereign Platform). The company also offers an innovative pTau217 blood test for earlier Alzheimer's diagnosis.

Differentiator

Problem solved

Functional benefit

Brands

• Cerballiance: Network of routine clinical pathology laboratories in France
• Cerba Research
• Cerba Path
• Cerba Vet
• Cerba Xpert
• CerbACT Asia
• Institut Cerba
• Cerba Lancet Africa
• Cerba HealthCare Italia
• Cerba HealthCare Belgium

Products and services

• Routine Clinical Pathology (Cerballiance network)

Quantifiable outcome

• 47 million patients served annually through global laboratory network
• +4 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability7 records

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• OUTSCALE (Dassault Systèmes)coreTechnology or Integration · 12 February 2026Partnership to develop the 'OUTSCALE Healthcare Sovereign Platform' for managing patient care through AI and digital technology. The platform is hosted on sovereign cloud infrastructure and aims to enhance security, efficiency, and patient experience across Cerba's laboratories.
• GMT SciencecoreStrategic or Co-development Partner · 20 February 2025GMT Science joined Cerba's virtual incubator to develop microbiome-based diagnostic tests. Cerba provides open innovation support for developing in vitro diagnostics using AI-analyzed metagenomics for oncology and cardiometabolic diseases.
• Nexus Gulf HealthcarecoreStrategic or Co-development Partner · 19 October 2023Joint venture to create Cerba HealthCare Saudi Arabia to contribute to healthcare system transformation in Saudi Arabia.
• International Clinical Laboratories (ICL)coreStrategic or Co-development Partner · 1 January 2022Strategic partnership with ICL in Ethiopia to strengthen diagnostic capabilities in African countries facing COVID-19 crisis.
• Lifebrain (Italy)coreStrategic or Co-development Partner · 1 January 2021Acquisition of Lifebrain Italian laboratories making Cerba HealthCare the market leader in medical diagnosis in Italy. Deal valued at nearly €1.2 billion.
• LabexacoreStrategic or Co-development Partner · 1 January 2021Acquisition of Labexa, a leading clinical pathology group in the Nouvelle Aquitaine region, strengthening Cerba's territorial presence in France.
• Loop MedicalcoreStrategic or Co-development PartnerPartnership to validate Loop Medical's needle-free blood sampling device. Cerba provides technical, scientific, and medical support to finalize development and refine market access strategy for this revolutionary solution that improves patient experience and sample traceability.
• Cerba Lancet AfricacoreStrategic or Co-development PartnerGroup's establishment in Africa in partnership with Lancet Laboratories, South Africa's leader in clinical pathology. Strategic joint venture to develop laboratory network across Africa.
• CerbACT AsiacoreStrategic or Co-development PartnerStrategic joint venture between Cerba Research and ACT Genomics to create purpose-built lab facility in Taiwan covering the Asia Pacific region for advanced diagnostics.
• Viroclinics-DDLcoreStrategic or Co-development PartnerAcquisition of Viroclinics-DDL, a fast-growing global virology and immunology contract research organization (CRO) to expand clinical trials activities.
• CIRION BioPharma ResearchcoreStrategic or Co-development PartnerAcquisition of Canadian contract research laboratory to expand bioanalytical capabilities and shorten time-to-deploy complex clinical trials.
• The Drone OfficeminorStrategic or Co-development PartnerPartnership to analyze drone logistics opportunities in medical biology, exploring use cases for emergency services, cancer screening in Africa, and sample transport.
• University of BourgogneminorStrategic or Co-development PartnerAcademic partnership for joint doctoral thesis on whole exome sequencing to identify new genes involved in rare genetic diseases.
• Inter MilanminorGTM or Marketing PartnerCerba HealthCare Italia served as Official Lab Partner for Inter Milan football club during 2022-23 season.

Scale indicators8 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Unilabs: European clinical diagnostics provider operating routine and specialty laboratory services across multiple European countries. With significant presence in Switzerland, Spain, Portugal, and other European markets, Unilabs directly competes with Cerba's European laboratory operations.
• Synlab: Major European clinical diagnostics provider operating routine and specialized laboratory services. Synlab's pan-European footprint and similar focus on medical diagnostics, particularly in France and Germany, makes it a direct competitor to Cerba's Cerballiance and specialized laboratory operations.
• Eurofins Scientific: Global leader in clinical diagnostics and laboratory testing services, with extensive European presence in routine and specialized testing. Both companies operate large laboratory networks serving healthcare professionals and patients across multiple countries, making them direct competitors in routine clinical pathology.

Broad incumbents

• Sonic Healthcare: Global diagnostic healthcare company with operations in laboratory medicine across multiple continents. As a large incumbent with broader geographic coverage including Australia, US, and Europe, it represents comparable scale and services to Cerba's international laboratory network.
• Labcorp: One of the world's largest clinical laboratory networks, offering routine and specialized diagnostics plus clinical trial services. Labcorp's clinical trials division and central laboratory services directly overlap with Cerba Research's offerings.
• BioMérieux: French in vitro diagnostics company focused on microbiology and infectious disease testing. Both companies share French roots and expertise in IVD, though BioMérieux primarily manufactures diagnostic reagents while Cerba operates testing services.
• Quest Diagnostics: Leading provider of diagnostic information services with extensive routine and specialty testing capabilities. While primarily US-focused, Quest's advanced diagnostics portfolio and clinical trials services are comparable to Cerba's specialized testing and research offerings.

Others

• IQVIA: Global clinical research services and healthcare intelligence company. While IQVIA's former managing director in France (Jean-Marc Aubert) joined Cerba, IQVIA's broader CRO and clinical trials services overlap with Cerba Research's pharmaceutical services business.
• Charles River Laboratories: Provider of clinical trials services and laboratory testing for pharmaceutical development. Charles River's central laboratory and clinical trial support services are comparable to Cerba Research's offerings for pharmaceutical and biotech clients.

Regional players

• Lancet Laboratories: South Africa's leading clinical pathology laboratory and Cerba's JV partner for Cerba Lancet Africa. Lancet's African operations complement rather than directly compete with Cerba's core European markets, while sharing similar routine and specialized testing capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cerba-healthcare

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries15 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerba HealthCare S.A.S.